All news

Ionis climbs 6.4% on two-year DAWNZERA data

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Ionis Pharmaceuticals shares rose 6.4% after Q3 2026 revenue of US$242.72 million and a net loss of US

Read original source

IONS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.